LifeStance (LFST) Q3 2026 earnings review
LifeStance raises its yearly plan, but fourth-quarter growth slows
LifeStance, one of America's largest outpatient mental healthcare networks, grew revenue fast while turning a bigger share of it into profit. Third-quarter revenue rose 25% to $456 million as the group added 321 clinicians and collected 7% more per patient visit. Chief executive Dave Bourdon raised the full-year outlook for a third time, though by our math the fourth-quarter plan has sales growth slowing to 19%.
| Revenue | $455.9M +25% from a year ago |
|---|---|
| Total revenue per visit | $169.70 +7.3% from a year ago |
| Adjusted EBITDA margin | 15.0% 11.1% a year ago |
| Full-year revenue outlook | Raised $46M middle of the range: 23% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because higher pay per visit and fuller clinics lifted the full-year profit plan close to the company's multi-year margin target two years early. The new fourth-quarter outlook also sits above what the prior plan implied by our math, showing the earlier forecast was cautious rather than that the year-end slowdown is gone. One caution: $122 million of share buybacks this year have not reduced the diluted share count.
The question now is whether the fourth-quarter slowdown in the outlook is routine caution or the real impact of tougher productivity comparisons. If it is caution, revenue and margins will beat the 19% growth and 13% margin plan; if comparisons bite, growth will converge toward the 11% clinician hiring pace. Fourth-quarter results and the initial 2027 outlook will settle it.
🐂 Bull Case
Clinic and Overhead Leverage Lifted Profit Margins
LifeStance is turning a much larger share of its revenue into profit as its clinics fill up. Adjusted EBITDA, which is operating cash profit before stock compensation and one-off items, rose 70% from a year ago to $68.4 million, beating the top of the company's $49–59 million outlook. That lifted the Adjusted EBITDA margin by 3.9 percentage points to 15.0% of revenue.
- Center costs (clinic pay and rent, excluding depreciation): 64.6% of revenue, down 3.4 percentage points from a year ago
- General and administrative expenses (corporate overhead and billing): 24.9% of revenue, down 1.4 percentage points
- Net income: $22.4 million, or $24.7 million by our math before a $2.3 million charge to revalue acquisition payouts
The company said margins rose because of higher pay per visit, "lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses". With the full-year outlook now pointing to a 14.1% margin by our math, the mental health provider is already running near its multi-year mid-teens target.
What to watch: general and administrative expenses as a percentage of revenue in the fourth quarter. A reading below 25% would show that second-half corporate spending is not reversing the overhead gains.
Higher Revenue Per Visit Carried Top-Line Growth
Higher insurance rates and specialty treatments are lifting what the business collects on each appointment. Total revenue per visit, the average amount earned per patient session, rose 7.3% from a year ago by our math to $169.70. That beat the 6.1% gain in the second quarter and the 3.0% increase in the first quarter.
Chief executive Dave Bourdon said "our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence". TMS (magnetic brain stimulation for depression) and Spravato (a nasal spray for severe depression) are higher-priced specialty treatments that sit alongside standard therapy. Together with one small clinic acquisition in the quarter, higher revenue per visit kept total sales growth at 25.3%.
What to watch: total revenue per visit in the fourth quarter against last year's $159.60 baseline. Holding near $170 would mean rate gains can keep carrying revenue as visit growth cools.
Clinician Hiring Accelerated While Productivity Held Up
The outpatient mental health group grows by hiring psychiatrists, nurses, psychologists, and therapists, and by filling more of their schedules. In the third quarter, it added 321 net new clinicians, up from 193 in the second quarter and 288 a year ago, bringing the total roster up 11% to 8,863.
Total patient visits rose 17% from a year ago to 2.69 million, as the business opened 8 new clinics to reach 20 for the year. By our math, visits per ending clinician still rose 5.4% from a year ago even against a tougher comparison from last autumn, showing that therapists are handling fuller caseloads without slowing down recruiting.
What to watch: net clinician additions in the fourth quarter, when hiring usually slows for the holidays. Adding more than last fourth quarter's 44 clinicians would set up double-digit capacity growth for 2027.
🐻 Bear Case
Buybacks Only Offset Dilution and Stockholder Sales
LifeStance pitches its capital plan as a disciplined return of cash to shareholders, having spent $122.4 million on share buybacks in the first nine months of 2026. By our math, the company spent $24.8 million on repurchases in the third quarter alone, plus $24.9 million year to date to cover employee stock taxes.
Yet the diluted share count, which divides net profit to calculate earnings per share, rose 0.6% from a year ago by our math to 391.2 million. At the same time, the business paid $0.5 million in the quarter ($1.5 million year to date) in legal and advisory fees for "underwritten public offerings of shares of our common stock by certain selling stockholders". The buybacks are absorbing employee stock grants ($53.1 million year to date) and early backer exits rather than shrinking the diluted share count.
What to watch: diluted weighted-average shares and secondary offering costs in the fourth quarter. A rising share count alongside more cash buybacks would confirm that repurchases only tread water against dilution.
Fourth-Quarter Plan Points to Slower Growth
"The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations," chief executive Dave Bourdon said. Even after raising the full-year plan, the fourth-quarter outlook calls for $446–466 million in revenue and $56–64 million in Adjusted EBITDA.
By our math, the middle of that fourth-quarter plan means revenue is flat from the third quarter and year-over-year growth slows from 25.3% to 19.3%. It also puts the Adjusted EBITDA margin at 13.2% by our math, down 1.8 percentage points from the third quarter. Beating the prior implied fourth-quarter range shows the earlier plan was cautious, not that the year-end slowdown is gone.
What to watch: fourth-quarter visit growth and Adjusted EBITDA margin against the 13.2% midpoint. A margin drop toward 13% would show that tougher productivity comparisons and year-end expenses are biting.
New Patient Record System Costs Are Rising
Bourdon highlighted "the implementation of our new EHR", which is the electronic health record software clinicians use to chart visits and bill insurers. In the Adjusted EBITDA table, the company excluded $1.7 million in third-quarter costs ($2.7 million year to date) for "evaluating and implementing a critical enterprise-wide scalable electronic health resources system".
Those excluded software setup costs nearly doubled from $0.9 million in the second quarter and $0.1 million in the first quarter. Moving nearly 8,900 clinicians onto a new scheduling and billing platform next year carries the risk of temporary booking slowdowns while excluding the setup bill from headline profit.
What to watch: the 2027 rollout schedule and expected clinician productivity impact when full-year 2027 targets arrive next quarter. A rollout that lowers 2027 visit growth would weigh on clinic margins.
Risks This Quarter Didn't Answer
Three standing operating and regulatory concerns received no new data in the third-quarter earnings release or presentation.
- Clinician turnover: neither the release nor the slides disclosed the clinician retention rate, leaving only net additions visible.
- Insurance concentration and audits: revenue concentration among top private insurers and retroactive billing audit activity were not updated in the release and await the quarterly 10-Q filing.
- Government payer exposure and lawsuits: the share of revenue from Medicaid and Medicare, which faces federal rule changes in 2027, was not in the release, while class-action litigation expenses were $34,000 in the quarter.
💲 Other KPIs
Free cash flow — operating cash left after buying clinic equipment and software — rose 31.8% from a year ago by our math to $22.4 million. It stepped down from $87.9 million in the second quarter because third-quarter operating cash flow was $37.0 million and capital spending rose to $14.7 million (3.2% of revenue).
Money owed by patients and insurers for completed visits stood at $120.9 million, down 0.1% from $121.1 million a year ago by our math even as quarterly revenue grew 25.3%. From the end of 2025, receivables rose $25.2 million, absorbing $24.4 million of operating cash over the first nine months.
The healthcare provider ended the quarter with $255.5 million in long-term debt and $218.8 million in cash, leaving $36.7 million in debt net of cash by our math. Total long-term debt fell from $269.4 million a year ago as the group paid down $10.9 million of principal during the first nine months.
🔮 Guidance
Raised. The middle of the full-year sales plan moved up $46 million to $1.751 billion, or 22.9% growth from 2025 by our math. It is the third straight raise this year, and the increases have grown larger: +$25 million in the first quarter, +$45 million in the second, and +$46 million now.
New. The fourth-quarter plan calls for 19.3% growth from a year ago at the $456 million middle of the range by our math, down from 25.3% in the third quarter. LifeStance has beaten its quarterly revenue midpoint four straight times by an average of 3.9% by our math, which would put fourth-quarter revenue near $474 million if the pattern holds.
Raised. Clinic profit before corporate overhead and depreciation moved up $24 million at the middle of the range to $606 million, or 31.4% growth from last year by our math. That follows raises of $21 million in the first quarter and $23 million in the second quarter.
New. At the $156 million middle of the range, fourth-quarter clinic profit grows 23.5% from a year ago by our math, down from 38.4% growth in the third quarter. That implies a clinic margin of 34.2% of revenue at the midpoints, compared with 35.4% in the third quarter.
Raised. The full-year cash operating profit outlook rose $21 million at the middle of the range to $246 million, or 56.0% growth from 2025 by our math. This third raise is the largest of the year (+$15 million, +$15 million, +$21 million) and lifts the implied full-year margin to 14.1%.
New. The plan points to $60 million at the middle of the range, up 23.0% from a year ago by our math after 70.0% growth in the third quarter. At the midpoints, the fourth-quarter margin steps down to 13.2% from 15.0% in the third quarter.
Unchanged. The presentation keeps the full-year planning assumption at 20 to 30 new clinic openings. Having opened 8 centers in the third quarter and 20 through the first nine months, the group has already reached the bottom of its annual target.
❓ Key Questions
What drove the 7% jump in revenue per visit?
Total revenue per visit rose 7.3% from a year ago to $169.70, the fastest gain of the year. Management did not break out how much came from standard insurance rate increases versus higher-priced TMS and Spravato treatments.
Why does the Q4 outlook model a margin drop?
At the middle of the fourth-quarter ranges, Adjusted EBITDA margin drops to 13.2% from 15.0% in the third quarter on flat sequential revenue. Investors need to know how much of that step-down is holiday visit seasonality versus new corporate spending.
What is the current clinician retention rate?
Net clinician additions hit 321 in the third quarter, but the release gives no gross hiring or turnover numbers. Without the retention rate, readers cannot tell if recruitment is getting easier or simply replacing departing therapists.
How will the 2027 patient record rollout affect bookings?
Consulting and setup costs for the new electronic health record system nearly doubled from last quarter to $1.7 million. Management has not yet detailed the 2027 rollout waves or how much clinician time the training will consume.